IFNAR1 and infection: The protective immunity of the VLPs in vivo and the potential of the VLPs to induce antibody-dependent enhancement of infection (ADE) will be investigated further in a suitable animal model, e.g., A129 (type I interferon receptor-deficient) or wild-type mice treated with an anti-IFNAR1 antibody.